Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 100: Sotorasib in KRAS p.G12C Mutant Advanced Solid Tumors
NCT03600883Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2018
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of sotorasib in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Aug 2018; status: completed.
02
Drugs
sotorasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03600883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600883.